316 related articles for article (PubMed ID: 22941914)
1. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.
Zschüntzsch J; Voss J; Creus K; Sehmisch S; Raju R; Dalakas MC; Schmidt J
Arthritis Rheum; 2012 Dec; 64(12):4094-103. PubMed ID: 22941914
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death.
Schmidt J; Barthel K; Zschüntzsch J; Muth IE; Swindle EJ; Hombach A; Sehmisch S; Wrede A; Lühder F; Gold R; Dalakas MC
Brain; 2012 Apr; 135(Pt 4):1102-14. PubMed ID: 22436237
[TBL] [Abstract][Full Text] [Related]
3. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid.
Muth IE; Barthel K; Bähr M; Dalakas MC; Schmidt J
J Neurol Neurosurg Psychiatry; 2009 Dec; 80(12):1344-9. PubMed ID: 19470495
[TBL] [Abstract][Full Text] [Related]
4. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.
Schmidt K; Kleinschnitz K; Rakocevic G; Dalakas MC; Schmidt J
BMC Neurol; 2016 Apr; 16():48. PubMed ID: 27083892
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
Raju R; Dalakas MC
Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
[TBL] [Abstract][Full Text] [Related]
6. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle.
Schmidt J; Barthel K; Wrede A; Salajegheh M; Bähr M; Dalakas MC
Brain; 2008 May; 131(Pt 5):1228-40. PubMed ID: 18420712
[TBL] [Abstract][Full Text] [Related]
7. HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis.
Muth IE; Zschüntzsch J; Kleinschnitz K; Wrede A; Gerhardt E; Balcarek P; Schreiber-Katz O; Zierz S; Dalakas MC; Voll RE; Schmidt J
Exp Neurol; 2015 Sep; 271():189-97. PubMed ID: 26048613
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis.
Askanas V; Engel WK; Nogalska A
J Neuropathol Exp Neurol; 2012 Aug; 71(8):680-93. PubMed ID: 22805774
[TBL] [Abstract][Full Text] [Related]
9. [Pathogenesis of inclusion body myositis: autoimmune or degenerative disease?].
Uruha A; Nishino I
Brain Nerve; 2013 Nov; 65(11):1291-8. PubMed ID: 24200607
[TBL] [Abstract][Full Text] [Related]
10. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity.
Schmidt J; Rakocevic G; Raju R; Dalakas MC
Brain; 2004 May; 127(Pt 5):1182-90. PubMed ID: 15047591
[TBL] [Abstract][Full Text] [Related]
11. Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers.
Wójcik S; Engel WK; McFerrin J; Askanas V
Acta Neuropathol; 2005 Aug; 110(2):173-7. PubMed ID: 15983828
[TBL] [Abstract][Full Text] [Related]
12. TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis.
Morosetti R; Gliubizzi C; Sancricca C; Broccolini A; Gidaro T; Lucchini M; Mirabella M
Am J Pathol; 2012 Apr; 180(4):1603-13. PubMed ID: 22314077
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin.
Amemiya K; Semino-Mora C; Granger RP; Dalakas MC
Clin Immunol; 2000 Feb; 94(2):99-104. PubMed ID: 10637094
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers.
Nogalska A; Engel WK; McFerrin J; Kokame K; Komano H; Askanas V
J Neurochem; 2006 Mar; 96(5):1491-9. PubMed ID: 16441512
[TBL] [Abstract][Full Text] [Related]
15. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers.
Nogalska A; D'Agostino C; Engel WK; Klein WL; Askanas V
Acta Neuropathol; 2010 Nov; 120(5):661-6. PubMed ID: 20711838
[TBL] [Abstract][Full Text] [Related]
16. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
Dalakas MC; Koffman B; Fujii M; Spector S; Sivakumar K; Cupler E
Neurology; 2001 Feb; 56(3):323-7. PubMed ID: 11171896
[TBL] [Abstract][Full Text] [Related]
17. Cell stress molecules in the skeletal muscle of GNE myopathy.
Fischer C; Kleinschnitz K; Wrede A; Muth I; Kruse N; Nishino I; Schmidt J
BMC Neurol; 2013 Mar; 13():24. PubMed ID: 23496965
[TBL] [Abstract][Full Text] [Related]
18. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis.
Lünemann JD; Schmidt J; Schmid D; Barthel K; Wrede A; Dalakas MC; Münz C
Ann Neurol; 2007 May; 61(5):476-83. PubMed ID: 17469125
[TBL] [Abstract][Full Text] [Related]
19. Messenger RNA degradation may be inhibited in sporadic inclusion body myositis.
Nakano S; Shinde A; Ito H; Ito H; Kusaka H
Neurology; 2005 Aug; 65(3):420-5. PubMed ID: 16087907
[TBL] [Abstract][Full Text] [Related]
20. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
